Connect with us

Health

Britain to sign cancer treatments deal with Germany’s BioNTech

Published

on

Research into new cancer treatments could be sped up by a government deal with a leading pharmaceutical company, British Health Secretary Steve Barclay has said.

Barclay is due to sign a memorandum of understanding with Germany’s BioNTech on Friday, to “ensure the best possible treatments are available as soon as possible” for cancer.

The agreement means cancer patients in England will get early access to trials exploring personalised messenger ribonucleic acid (mRNA) therapies, like cancer vaccines, possibly from as early as autumn this year.

BioNTech worked with Pfizer to develop the widely-used mRNA vaccination against COVID-19, and its partnership with the British government could deliver 10,000 doses of personalised therapies to British patients by 2030 through a new research and development hub.

Barclay said: “Once cancer is detected, we need to ensure the best possible treatments are available as soon as possible, including for breast, lung, and pancreatic cancer.

“BioNTech helped lead the world on a COVID-19 vaccine and they share our commitment to scientific advancement, innovation and cutting-edge scientific technology, making them perfect partners for a deal to work together on cancer vaccines.”

He added: “This partnership will mean that, from as early as September, our patients will be among the first to participate in trials and tests to provide targeted, personalised, and precision treatments using transformative new therapies to both treat the existing cancer and help stop it returning.

“This agreement builds on this government’s promise to increase research and development spending to £20 billion ($23.8 billion) per year and demonstrates the UK remains one of the most attractive places in the world for innovative companies to invest in research, trial new treatments and treat patients more effectively.”

Prof. Uğur Şahin, chief executive and co-founder of BioNTech said: “The UK successfully delivered COVID-19 vaccines so quickly because the National Health Service, academia, the regulator and the private sector worked together in an exemplary way.

“This agreement is a result of the lessons learnt from the COVID-19 pandemic.

“Drug development can be accelerated without cutting corners if everyone works seamlessly together towards the same goal.

“Today’s agreement shows we are committed to do the same for cancer patients.”

Şahin added: “Our goal is to accelerate the development of immunotherapies and vaccines using technologies we have been researching for over 20 years.

The collaboration will cover various cancer types and infectious diseases affecting collectively hundreds of millions of people worldwide.

“If successful, this collaboration has the potential to improve outcomes for patients and provide early access to our suite of cancer immunotherapies as well as to innovative vaccines against infectious diseases – in the UK and worldwide.”

Health

FG bans use of foreign syringes, needles in tertiary hospitals 

Published

on

The Federal Government has mandated all Chief Medical Directors (CMDs) and Medical Directors (MDs) of Federal Tertiary Hospitals to procure needles and syringes solely from NAFDAC-approved local manufacturers.

The new directive is contained in a circular addressed to all CMDs and MDs signed by the Minister of State for Health, Dr Tunji Alausa, on Friday.

The minister said that the directive was aimed at boosting domestic production and shielding the country’s manufacturing sector from the influx of foreign goods.

The circular also mandated NAFDAC to stop issuing licences for the importation of foreign manufactured needles and syringes.

Alausa said the health sector had dentified local pharmaceutical industries that produce needles and syringes that were in serious trouble because of the practice.

He also said that out of the nine local pharmaceutical companies that produced needles and syringes eight years ago, six have folded up due to the dumping of largely substandard goods into the market.

“Mr President has directed that this must stop. We all agreed to take the necessary steps to immediately remedy this sad situation.

“Pursuant to this, NAFDAC has been mandated to stop issuing licences for the importation of foreign manufactured needles and syringes.

“It is also to de-list companies involved in the importation of these products going forward,” he said.

Alausa said ”all our tertiary hospitals are hereby directed to procure needles and syringes for your hospital needs from only the NAFDAC-approved local manufacturers listed below are listed either directly or through any of their vendors.

“EL-Salmat Pharmaceuticals Company Ltd Block, Brand Name: Salmaject, HMA Medical Ltd., with brand Name: Deleject and Afrimedical Manufacturing and Supplies Ltd.”

He also listed some of the distributors of the listed companies in some states of the Federation for easy access to assist in making the procurement process easier in the various institutions.

Continue Reading

Health

KDSG trains 180 Red Cross volunteers on Lassa Fever intervention

Published

on

The Kaduna State Ministry of Health has begun a three-day training for 180 Red Cross volunteers on Lassa fever intervention.

The training, which is facilitated by the ministry and funded by the Red Cross, is meant to equip the volunteers selected from 5 LGAs in the state with necessary skills.

The volunteers were drawn from Zaria, Igabi, Kaduna South, Kaduna North and Chikun Divisions.

The State Epidemiologist, Dr Jeremiah Dikwu, said the volunteers were trained with  the knowledge needed to massively intervene during cases of Lassa fever in the state.

He said that the intervention would include Risk Communication and Active Case Search, Psychological First Aid, Rodent Control and Hygiene Promotion for the next 3 months.

Dikwu said the training started  with 30 volunteers on surveillance and would end with the training of 150 volunteers on Risk Communication and Community Engagement .

According to him, Lassa fever is a viral hemorrhagic fever transmitted by rats.

He added that Lassa fever  has been known since the 1950s, but the virus was not identified until 1969, when two missionary nurses died from it in the town of Lassa in Nigeria.

Dikwu added that Lassa fever was caused by a single stranded RNA virus and disseminated systemic primary viral infection.

“The main feature of fatal illness is impaired or delayed cellular immunity leading to fulminant viraemia,” he said

The epidemiologist said that Lassa fever presented  symptoms and signs indistinguishable from those of febrile illnesses such as malaria and other viral hemorrhagic fevers such as Ebola.

“It is difficult to diagnose clinically but should be suspected in patients with fever (e”38°C) not responding adequately to antimalarial and antibiotic drugs.

“The most useful clinical predictors of Lassa fever are fever, pharyngitis, retrosternal pain, and proteinuria for diagnosis; and fever, sore throat, and vomiting for outcome,” Dikwu said.

He said that Ribavirin and general support were needed.

“Ribavirin is almost twice as effective when given intravenously as when taken orally, and if given within six days of the start of illness it may reduce deaths by 90 percent.

“Dehydration, oedema, hypotension, and poor renal function are common; fluid replacement or the use of blood transfusion requires careful monitoring,” he said.

 Dikwu said the volunteers would  be carrying out Risk communication and Community engagement, Active Case Search, Psychological First Aid, Rodent Control and Hygiene Promotion

Continue Reading

Health

Assembly passes Kano Pre-Marital Health Screening Bill

Published

on

Kano State House of Assembly has passed a bill for a law to compel intending couples to undergo HIV, hepatitis and sickle cell anaemia screening before marriage.

The passage followed deliberations in the Committee of the Whole House during plenary session,
presided over by the Speaker, Ismail Falgore on Monday in Kano.

After deliberations, the lawmakers approved the 3rd reading of the bill, read by the Deputy Clerk, Alhaji Nasiru Magaji.

Shortly after passage of the bill, the Majority Leader of the house, Lawan Hussein (NNPP-Dala), stated that “any person
intending to marry shall first submit self for medical examinations.”

He said the bill was considered and passed after the 3rd reading, following various legislative processes.

The leader further said that the bill was passed because the state had been battling with different health issues, including
HIV because people go into marriages without medical screening.

He said that the bill, if signed into law, would save many lives and curb the spread of life-threatening diseases.

“The bill will safeguard the health of citizens by institutionalising pre-marital testing to check the spread of diseases
like hepatitis, HIV and sickle cell anaemia,” he added.

Continue Reading

Trending